AI could revolutionize heart attack care, new study hopes
NCT ID NCT07367399
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new AI-powered decision support system designed to help doctors diagnose and treat acute myocardial infarction (heart attack) more quickly and effectively. The system aims to address common delays in care, such as slow diagnosis in clinics and low compliance with treatment guidelines. Researchers will enroll 15,000 patients across multiple hospitals to see if the AI can improve outcomes like reducing major heart events and deaths.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- AI-driven clinical decision support system
- What this could lead to
- If successful, this could provide a proven way to use AI to speed up heart attack diagnosis and treatment, potentially saving lives and reducing complications.
- What could go wrong
- This is an early-stage implementation study focused on testing the system's feasibility and integration, not a direct test of patient outcomes. The AI may not work well in all hospital settings or may face technical hurdles.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 15,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2018
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population comprised consecutive adult patients (aged ≥ 18 years) diagnosed with acute myocardial infarction (AMI) and admitted to Beijing Anzhen Hospital. AMI was defined according to the Fourth Universal Definition of Myocardial Infarction, encompassing both ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). Inclusion required documented acute myocardial injury (rise/fall of cardiac troponin above the 99th percentile URL) alongside clinical evidence of ischemia. All participants provided written informed consent. We excluded patients with a life expectancy \< 12 months due to non-cardiac comorbidities, those with severe cognitive impairment hindering assessment, and individuals unable to comply with the long-term follow-up protocol. The study was approved by the Institutional Ethics Committee and conducted in strict accordance with the Declaration of Helsinki.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients meeting the diagnostic criteria for acute myocardial infarction (AMI). Acute Myocardial Infarction (AMI) encompasses both ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). According to the Fourth Universal Definition of Myocardial Infarction, myocardial injury is defined as the detection of an elevated cardiac troponin (cTn) value above the 99th percentile upper reference limit (URL). The injury is considered acute if there is a rise and/or fall of cTn values. The clinical definition of myocardial infarction (MI) requires the presence of acute myocardial injury, confirmed by abnormal cardiac biomarkers, in the setting of evidence of acute myocardial ischemia. Clinical evidence of ischemia includes at least one of the following: ①Symptoms of myocardial ischemia; ②New ischemic ECG changes; ③Development of pathological Q waves; ④Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology; ⑤Identification of a coronary thrombus by angiography or autopsy. 2. Patients who have provided written informed consent. Exclusion Criteria: 1. patients with a life expectancy \< 12 months due to non-cardiac comorbidities; 2. those with severe cognitive impairment hindering assessment; 3. individuals unable to comply with the long-term follow-up protocol
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute myocardial infarction are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Anzhen Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Every minute counts: study tracks how delays shape heart attack survival
- Stick-On patch aims to catch dangerous heart decline sooner
- Sleep apnea clues may unmask hidden heart risks in survivors
- Can new imaging and genetics unlock the secrets of heart attacks?
- Blood test clues: could two proteins predict heart failure after a heart attack?
- Which strategy wins for heart attack patients with multiple blocked arteries?